Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: Effects of exogenous MMP inhibition

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 1 57-1, 2005, Pages

  Ikonomidis, John S ^a   Hendrick, Jennifer W ^a   Parkhurst, Andrea M ^a   Herron, Amanda R ^a   Escobar, Patricia G ^a   Dowdy, Kathryn B ^a   Stroud, Robert E ^a   Hapke, Elizabeth ^a   Zile, Michael R ^a   Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Heart failure; Myocardial hypertrophy; Transgenic model

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; PD 166793; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE CONDUCTION; HEART VENTRICLE REMODELING; HEART WEIGHT; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ZYMOGRAPHY;

ANIMALS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; OLIGOPEPTIDES; PRESSURE; STROKE VOLUME; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 19944365505     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00370.2004     Document Type: Article

References (41)

1. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrate: the good, the bad, and the ugly. Am J Physiol Cell Physiol 271: C1424-C1437, 1996.
2. Birnbaum Y, Chamoun AJ, Conti VR, and Uretsky BF. Mitral regurgitation following acute myocardial infarction. Coron Artery Dis 13: 337-344, 2002.
3. Chapman RE, Scott AA, Deschamps AM, Lowry AS, Stroud RE, Ikonomidis JS, and Spinale FG. Matrix metalloproteinase abundance in human myocardial fibroblasts: effect of sustained pharmacological matrix metalloproteinase inhibition. J Mol Cell Cardiol 35: 539-548, 2003.
4. Coghlan HC, Coghlan AR, Buckberg GD, Gharib M, and Cox JL. The structure and function of the helical heart and its buttress wrapping. III. The electric spiral of the heart: the hypothesis of the anisotropic conducting matrix. Semin Thorac Cardiovasc Surg 13: 333-341, 2001.
5. Cordis GA, Maulik N, and Das DK. Detection of oxidative stress in hearts by estimating the dinitrophenylhydrazine derivative of malonaldehyde. J Mol Cell Cardiol 27: 1645-1653, 1995.
6. Cox MJ, Hawkins UA, Holt BD, and Tyagi SC. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation 109: 2123-2128, 2004.
7. Cox MJ, Sood HS, Hunt MJ, Chandler D, Henegar JR, Aru GM, and Tyagi SC. Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 282: H1197-H1205, 2002.
8. Creemers E, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, Hauet AM, Simsic JM, Escobar GP, Smits J, Daemen M, Cleutjens J, Zile MR, and Spinale FG. Deficiency of the tissue inhibitor of matrix metalloproteinase-1 gene exacerbates LV remodeling following myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284: H122-H132, 2003.
9. Creemers EEJM, Cleutjens JPM, Smits JFM, and Daemen MJAP. Matrix metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure? Circ Res 89: 201-210, 2001.
10. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, and Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329: 23-38, 2003.
11. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb A, Libby P, and Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106: 55-62, 2000.
12. Eddy AA, Kim H, Lopez-Guisa J, Oda T, and Soloway PD. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int 58: 618-628, 2000.
13. Feldman MD, Mao Y, Valvano JW, Pearce JA, and Freeman GL. Development of a multifrequency conductance catheter-based system to determine LV function in mice. Am J Physiol Heart Circ Physiol 279: H1411-H1420, 2000.
14. Figueroa JE, Oubre J, and Vijayagopal P. Modulation of vascular smooth muscle cell proteoglycan synthesis by the extracellular matrix. J Cell Physiol 198: 302-309, 2004.
15. Georgakopoulos D, Mitzner WA, Chen CH, Byrne BJ, Millar HD, Hare JM, and Kass DA. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol Heart Circ Physiol 274: H1416-H1422, 1998.
16. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, and He C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloprotease designated TIMP. Proc Natl Acad Sci USA 86: 8207-8211, 1989.
17. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, and Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271: 30375-30380, 1996.
18. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, and Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285: H1229-H1235, 2003.
19. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dsyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Evi M, Nube O, Baker A, Keshet E, Lupu F, Herger JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, and Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteitiases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5: 1135-1142, 1999.
20. Janssen BJ, DeCelle T, Debets JJ, Brouns AE, Callahan MF, and Smith TL. Effects of anesthetics on systemic hemodynamics in mice. Am J Physiol Heart Circ Physiol 287: H1618-H1624, 2004.
21. Jiang Y, Goldberg ID, and Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245-2252, 2002.
22. Kim GW, Gashe Y, Grzeschik S, Copin JC, Maier CM, and Chan PH. Neurodegeneration in striatum induced by the mitochondrial toxin 3-nitropropionic acid: role of matrix metalloproteinase-9 in early blood-brain barrier disruption? J Neurosci 23: 8733-8742, 2003.
23. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, and D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 106: 857-866, 2002.
24. Lindsey M, Gannon J, Aikawa M, Schoen F, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell P, and Lee R. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105: 753-758, 2002.
25. Luoma JS, Stralin P, Marklund SL, Hiltunen TP, Sarkioja T, and Yla-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 18: 157-167, 1998.
26. Meli DN, Christen S, and Leib SL. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis 187: 1411-1415, 2003.
27. Mukherjee R, Widener CE, Brinsa TA, Dowdy KB, Scott AA, Sample JA, Hendrick JW, Escobar GP, Joffs C, Lucas DG, Zile MR, and Spinale FG. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107: 618-625, 2003.
28. Nakamura K, Toda H, Hatano Y, and Mori K. Comparison of the direct effects of sevoflurane, isoflurane and halothane on isolated canine coronary arteries. Can J Anaesth 40: 257-261, 1993.
29. Nian M, Lee P, Khaper N, and Liu P. Inflammatory cytokines and post myocardial infarction remodeling. Circ Res 94: 1543-1553, 2004.
30. Nothnick WB, Soloway PD, and Curry TE Jr. Pattern of messenger ribonucleic acid expression of tissue inhibitors of metalloproteinases (TIMPs) during testicular maturation in male mice lacking a functional TIMP-1 gene. Biol Reprod 59: 364-370, 1998.
31. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TMA, Coker ML, Etoh T, and Spinale FG. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103: 2303-2309, 2001.
32. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, and Spinale FG. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 32: 109-120, 2000.
33. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530, 2002.
34. Spinale FG, Krombach RS, Coker ML, Mukherjee R, Thomas CV, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, and Zile MR. Matrix metalloproteinase inhibition during developing congestive heart failure in pigs: effects on left ventricular geometry and function. Circ Res 85: 364-376, 1999.
35. Stroud JD, Baicu CF, Barnes MA, Spinale FG, and Zile MM. Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol 282: H2324-H2335, 2002.
36. Umashankara M, Babu IR, and Ganesh KN. Two prolines with a difference: contrasting stereoelectronic effects of 4R/S-aminoproline on triplex stability in collagen peptides [pro(X)-pro(Y)-Gly]n. Chem Commun (Camb) 20: 2606-2607, 2003.
37. Vincenti MP. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. In: Matrix Metalloproteinase Protocols. Totowa, NJ: Humana, 2001, p. 121-148.
38. Wang P and Zweier JL. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitrite-mediated reperfusion injury. J Biol Chem 271: 29223-29230, 1996.
39. Wilson EM, Moainie SL, Baskin JM, Lowry AS, Deschamps AM, Mukherjee R, Guy TS, St. John-Sutton MG, Gorman JH III, Edmunds LH Jr, Gorman RC, and Spinale FG. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 107: 2857-2863, 2003.
40. Woessner JF and Nagase H. Functions of the TIMPs. In: Matrix Metalloproteinases and TlMPs. Oxford, UK: Oxford University Press, 2000, p. 130-135.
41. Zile MR and Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. II. Causal mechanisms and treatment. Circulation 105: 1503-1508, 2002.